Get the Stockscreener App
11.16
0.81%
0.09
After Hours:
11.16
Theravance Biopharma Inc stock is traded at $11.16, with a volume of 157.03K.
It is up +0.81% in the last 24 hours and up +1.18% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$11.07
Open:
$11.01
24h Volume:
157.03K
Relative Volume:
0.59
Market Cap:
$558.01M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-12.13
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+0.27%
1M Performance:
+1.18%
6M Performance:
+18.98%
1Y Performance:
+10.39%
1-Day Range:
$10.97
$11.18
1-Week Range:
$10.90
$11.26
52-Week Range:
$7.44
$11.88
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
11.16 | 553.51M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
What is the risk reward ratio of investing in Theravance Biopharma Inc. stockBreakout Stocks Updates With Proven Results - jammulinksnews.com
Applying Wyckoff theory to Theravance Biopharma Inc. stockFree Triple Digit Return Stock Predictions - Newser
How Theravance Biopharma Inc. stock performs during market volatilityValue Holding Return Summary With Outlook - Newser
How to use a screener to detect Theravance Biopharma Inc. breakoutsFree Stable Entry High Return Opportunities - Newser
Is Theravance Biopharma Inc. stock a good hedge against inflationEquity Portfolio Outlook and Performance Summary - Newser
What’s the recovery path for long term holders of Theravance Biopharma Inc. - Newser
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by GSA Capital Partners LLP - Defense World
What makes Theravance Biopharma Inc. stock price move sharplyPattern Breakout Tracker with Screener Tools - Newser
Theravance Biopharma Inc. Stock Performance After Earnings: Historical InsightsFuture Growth Stock Forecasting Strategy - Newser
What earnings revisions data tells us about Theravance Biopharma Inc.Risk Balanced Picks for Safer Trading - Newser
What institutional flow reveals about Theravance Biopharma Inc.Trade Flow Monitor with Volume Tracker - Newser
Using Ichimoku Cloud for Theravance Biopharma Inc. technicals7-Day Equity Return Range Forecast Model - Newser
How strong is Theravance Biopharma Inc. company’s balance sheetBest Dividend Report For Fast Growth - jammulinksnews.com
How does Theravance Biopharma Inc. compare to its industry peersSwing Trade Review With Proven Results - jammulinksnews.com
What are analysts’ price targets for Theravance Biopharma Inc. in the next 12 monthsRapid market gains - jammulinksnews.com
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 - Lelezard
Theravance Biopharma Sets Q2 Earnings Date: Key Financial Results Coming August 12 After Market Close - Stock Titan
What institutional flow reveals about Theravance Biopharma Inc. 3-Day Market Movement Forecast Analysis - Newser
Applying Wyckoff theory to Theravance Biopharma Inc. stock Free Reliable Investment Entry Point Signals - Newser
Applying Wyckoff theory to Theravance Biopharma Inc. stock Investment Timeline and ROI Summary Report - Newser
How many analysts rate Theravance Biopharma Inc. as a “Buy”Achieve rapid returns with smart investment plans - jammulinksnews.com
Is Theravance Biopharma Inc. stock overvalued or undervaluedInvest confidently with data-driven strategies - jammulinksnews.com
What are the technical indicators suggesting about Theravance Biopharma Inc.Get expert analysis on top stock picks - jammulinksnews.com
What are the latest earnings results for Theravance Biopharma Inc.Consistent high-performance stocks - jammulinksnews.com
Moving Average Trends for Theravance Biopharma Inc. Stock: What They IndicateDaily Stock Watch Summary with Key Insights - Newser
Why Theravance Biopharma Inc. stock attracts strong analyst attentionEntry Level Low Risk Picks - Newser
Theravance Biopharma Inc. Stock Analysis and ForecastOutstanding capital appreciation - PrintWeekIndia
Is Theravance Biopharma Inc. a good long term investmentFree Predictions - Autocar Professional
What analysts say about Theravance Biopharma Inc. stockExtraordinary earning power - PrintWeekIndia
Theravance Biopharma to Participate in an Upcoming Investor Conference - 富途牛牛
Exclusive: Theravance Biopharma Leadership Reveals Strategic Updates at BTIG Conference Next Week - Stock Titan
What drives Theravance Biopharma Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):